The Outlook for Multiple Sclerosis: Targeted Therapy for Optimal Patient Outcomes Web Activity

• Release date: December 30, 2016
• Expiration date: June 30, 2018
• Estimated Time to Complete Activity: 1.5 hours
• Compatible with all modern browsers and mobile devices

DISTINGUISHED FACULTY

James Kenney, Jr., RPh, MBA Manager, Specialty and Pharmacy Contracts Harvard Pilgrim Health Care Click here for biography Scott Newsome, DO, MSCS Director, Neurology Outpatient Services Director, Neurology Infusion Center Division of Neuroimmunology and Neuroinfectious Diseases Health Guidance Organization Johns Hopkins School of Medicine Click here for biography Edmund Pezalla, MD, MPH Former National Medical Director, Pharmacy Policy and Strategy Aetna Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for multiple sclerosis (MS) patients including: physicians, pharmacists, and registered nurses

Statement of Need/Program Overview
Multiple sclerosis (MS) is a complex disease that requires a collaborative approach to care to achieve optimal patient care and outcomes. Given current constraints on health care expenditures, the relative cost-effectiveness of these therapies needs to be considered when making treatment decisions. Due to a lack of head to head trials it is difficult to determine which therapy would be most effective for MS; however, it is possible to evaluate current therapies based on their effects on sustained disability, relapse rate, lesion load, brain atrophy, and cognitive dysfunction. Members of the clinical team, as well as patients, need to coordinate these efforts when choosing the appropriate therapy and continually monitor the disease, manage symptoms and the psychological aspects of the disease, and engage the patient through coordinated patient education in order to achieve optimal clinical, economic, and humanistic outcomes.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate improved ability to:

• Use current and emerging clinical data to enhance therapeutic decision-making and optimize outcomes for MS treatments
• Implement the necessary collaborations, processes, and systems that will improve access to MS screening and drive successful MS treatment in a complicated new accountable care ecosystem
• Evaluate current treatment guidelines to select the optimal treatment for specific patient types
• Provide accurate and appropriate counsel as part of the managed care treatment team

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – 0809-9999-16-538-H01-P

Type of Activity
Application

Nursing Continuing Education

Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 30, 2016 through June 30, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.